Windtree Therapeutics Inc (WINT) Stock: What Does the Chart Say Friday?

Overall market sentiment has been high on Windtree Therapeutics Inc (WINT) stock lately. WINT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Windtree Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on WINT!

See Full WINT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With WINT Stock Today?

Windtree Therapeutics Inc (WINT) stock is trading at $0.70 as of 3:33 PM on Friday, Dec 29, a drop of -$0.02, or -3.06% from the previous closing price of $0.72. Volume today is above average. So far 446,192 shares have traded compared to average volume of 133,753 shares. The stock has traded between $0.67 and $0.74 so far today.

More About Windtree Therapeutics Inc

Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products. Click Here to get the full Stock Report for Windtree Therapeutics Inc stock.